Category - Markets

Piper Jaffray has initiated coverage of Inogen (NASDAQ:INGN) with a “neutral” rating and price target of $46. The stock closed at $41.07 on Wednesday. “We truly appreciate the unique technology the company has developed...

Leerink Partners has initiated coverage of Depomed (NASDAQ:DEPO) with an “outperform” rating and $21 price target. The stock closed at $14.62 on Wednesday. “Depomed’s Nucynta for chronic pain provides a differentiated...

EyeGate Pharmaceuticals (NASDAQ:EYEG) has acquired Jade Therapeutics, a closely-held company developing locally administered, polymer-based products designed to treat poorly-served ophthalmic indications. Jade’s...

Rodman & Renshaw has launched coverage of Nanosphere (NASDAQ:NSPH) with a “buy” rating and price target of $2. The stock closed at 87 cents on Monday. “In our view, the company’s Verigene system and test panels are...

Rodman & Renshaw has started coverage of BioSpecifics Technologies (NASDAQ:BSTC) with a “buy” rating and 12-month price target of $60. The stock closed at $35.97 on Monday. The company’s sole product is the...

Leerink Partners has initiated coverage of Proteostasis Therapeutics (NASDAQ: PTI) with an “outperform” rating and $13 price target in 12 months. The stock closed at $5.56 on Friday. Proteostasis’ lead candidate, PTI...

H.C. Wainwright has initiated coverage of Paratek Pharmaceuticals (NASDAQ:PRTK) with a “buy” rating and $32 price target. The stock closed at $15.51 on Friday. Paratek’s lead drug, omadacycline, is a broad-spectrum...

H.C. Wainwright has launched coverage of Actinium Pharmaceuticals (NASDAQ:ATNM) with a “buy” rating and a price target of $8. The stock closed at $1.98 on Friday. “We believe that due to a long history of pivotal...

Mark Breidenback of H.C. Wainwright has assumed coverage of uniQure NV (NASDAQ:QURE) with a “buy” rating and $30 price target. The stock closed at $14.89 on Tuesday. uniQure is developing gene therapies as long-acting...

William Blair & Co. has initiated coverage of Collegium Pharmaceutical (NASDAQ:COLL) with an “outperform” rating and price target of $35. The stock closed at $19.25 on Thursday. Collegium’s lead product, Xtampza ER...